Telix Pharmaceuticals (TLX) Payables (2023 - 2025)

Telix Pharmaceuticals (TLX) has 3 years of Payables data on file, last reported at $163.5 million in Q4 2025.

• Payables for Q4 2025 came in at $163.5 million, up 57.29% year-over-year; the trailing twelve-month figure through Dec 2025 was $163.5 million (up 57.29% YoY), and the FY2025 annual result was $163.5 million, up 57.29% from the prior year.
• Payables rose to $163.5 million in Q4 2025 per TLX's latest filing, from $103.9 million in the prior quarter.
• Over five years, Payables peaked at $163.5 million in Q4 2025 and troughed at $22.0 million in Q4 2023.
• A 3-year average of $96.5 million and a median of $103.9 million in 2024 frame the typical range for Payables.
• The sharpest annual moves came in 2024 and 2025: Payables jumped 372.3% in 2024, then soared 57.29% in 2025.
• A 3-year view of Payables shows it stood at $22.0 million in 2023, then jumped by 372.3% to $103.9 million in 2024, then soared by 57.29% to $163.5 million in 2025.
• Business Quant data shows TLX's Payables at $163.5 million in Q4 2025, $103.9 million in Q4 2024, and $22.0 million in Q4 2023.